Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.57 |
| ▸ | ESRRG | P62508 | 5/20 | 0.56 |
| ▸ | ESRRB | O95718 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187149 | 0.85 | ESRRG (0.60) | ESRRGESRRBCNR1PPARGPPARD | |
| SCHEMBL5177863 | 0.79 | ESRRG (0.70) | TRPV1ESRRGESRRBNPC1RAB9A | |
| SCHEMBL5178683 | 0.79 | CNR1 (0.48) | TRPV1CNR1VNN1MAPK14 | |
| SCHEMBL5176979 | 0.78 | ESRRG (0.72) | ESRRGESRRBCNR1NPC1RAB9A | |
| SCHEMBL3577619 | 0.78 | TRPV1 (0.69) | TRPV1CNR1MAPK14NAMPTNPC1 | |
| SCHEMBL5178676 | 0.76 | LMNA (0.57) | CNR1VNN1MAPK14 | |
| SCHEMBL3391028 | 0.75 | TRPV1 (0.65) | TRPV1CNR1MAPK14NAMPTRAB9A | |
| SCHEMBL27422506 | 0.74 | CNR1 (0.67) | TRPV1CNR1VNN1MAPK14NAMPT | |
| SCHEMBL7643257 | 0.74 | CNR1 (0.63) | TRPV1CNR1VNN1MAPK14NAMPT | |
| SCHEMBL5704409 | 0.74 | PPARG (0.62) | TRPV1PPARGPPARDPPARAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | TRPV1 1818/4885ESRRG 3392/4885ESRRB 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.